A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection

Gordon L. Phillips; Steven H. Bernstein; Jane L. Liesveld; Camille N. Abboud; Michael W. Becker; Louis S. Constine; J. J. Ifthikharuddin; John E. Loughner; Laurie A. Milner; David H. Vesole; Jonathan W. Friedberg

doi:10.1016/j.bbmt.2010.11.003

A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection

Gordon L. Phillips, Steven H. Bernstein, Jane L. Liesveld, Camille N. Abboud, Michael W. Becker, Louis S. Constine, J. J. Ifthikharuddin, John E. Loughner, Laurie A. Milner, David H. Vesole, Jonathan W. Friedberg

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m², a substantial increase from the usual dose of 140 mg/m² in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.

Original language	English
Pages (from-to)	1033-1042
Number of pages	10
Journal	Biology of Blood and Marrow Transplantation
Volume	17
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2010.11.003
State	Published - Jul 2011

Keywords

Amifostine
Autologous stem cell
Melphalan
Phase I
Regimen-related toxicity

Access to Document

10.1016/j.bbmt.2010.11.003

Cite this

Phillips, G. L., Bernstein, S. H., Liesveld, J. L., Abboud, C. N., Becker, M. W., Constine, L. S., Ifthikharuddin, J. J., Loughner, J. E., Milner, L. A., Vesole, D. H., & Friedberg, J. W. (2011). A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biology of Blood and Marrow Transplantation, 17(7), 1033-1042. https://doi.org/10.1016/j.bbmt.2010.11.003

@article{c183d0d4dd96469b99c4298bb007652b,

title = "A phase I trial: Dose escalation of melphalan in the {"}BEAM{"} regimen using amifostine cytoprotection",

abstract = "With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m2, a substantial increase from the usual dose of 140 mg/m2 in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.",

keywords = "Amifostine, Autologous stem cell, Melphalan, Phase I, Regimen-related toxicity",

author = "Phillips, {Gordon L.} and Bernstein, {Steven H.} and Liesveld, {Jane L.} and Abboud, {Camille N.} and Becker, {Michael W.} and Constine, {Louis S.} and Ifthikharuddin, {J. J.} and Loughner, {John E.} and Milner, {Laurie A.} and Vesole, {David H.} and Friedberg, {Jonathan W.}",

year = "2011",

month = jul,

doi = "10.1016/j.bbmt.2010.11.003",

language = "English",

volume = "17",

pages = "1033--1042",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

number = "7",

}

Phillips, GL, Bernstein, SH, Liesveld, JL, Abboud, CN, Becker, MW, Constine, LS, Ifthikharuddin, JJ, Loughner, JE, Milner, LA, Vesole, DH & Friedberg, JW 2011, 'A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection', Biology of Blood and Marrow Transplantation, vol. 17, no. 7, pp. 1033-1042. https://doi.org/10.1016/j.bbmt.2010.11.003

TY - JOUR

T1 - A phase I trial

T2 - Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection

AU - Phillips, Gordon L.

AU - Bernstein, Steven H.

AU - Liesveld, Jane L.

AU - Abboud, Camille N.

AU - Becker, Michael W.

AU - Constine, Louis S.

AU - Ifthikharuddin, J. J.

AU - Loughner, John E.

AU - Milner, Laurie A.

AU - Vesole, David H.

AU - Friedberg, Jonathan W.

PY - 2011/7

Y1 - 2011/7

N2 - With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m2, a substantial increase from the usual dose of 140 mg/m2 in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.

AB - With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m2, a substantial increase from the usual dose of 140 mg/m2 in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.

KW - Amifostine

KW - Autologous stem cell

KW - Melphalan

KW - Phase I

KW - Regimen-related toxicity

UR - http://www.scopus.com/inward/record.url?scp=79958749844&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.11.003

DO - 10.1016/j.bbmt.2010.11.003

M3 - Article

C2 - 21074630

AN - SCOPUS:79958749844

SN - 1083-8791

VL - 17

SP - 1033

EP - 1042

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -

A phase I trial: Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this